Sur­vey says drug com­mer­cial­iza­tion should stretch back, in­cor­po­rate dig­i­tal in­sights for doc­tors

The best time for phar­ma com­pa­nies to start talk­ing to doc­tors about a new drug is about 18 months be­fore launch, ac­cord­ing to new sur­vey da­ta.

While that may sound like a long time out, and well be­fore the FDA has weighed in on whether the drug is a go or no-go, it’s what sur­faced from physi­cians’ in­ter­views and sur­veys in PRE­CI­SION­ef­fect’s lat­est quar­ter­ly plat­form da­ta.

“Doc­tors are aware of what’s hap­pen­ing at the FDA and they’re aware what phar­ma is al­lowed to do and what they’re not al­lowed to do. But around that crit­i­cal point be­tween Phase II and Phase III, doc­tors want to start hear­ing from the com­pa­ny around the sci­ence,” said John Fitz­patrick, SVP of om­nichan­nel en­gage­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.